Health Condition 1: H401- Open-angle glaucoma Health Condition 2: null- Patients with glaucoma
Conditions
Interventions
Intervention1: Latanoprost: 0.005%
Control Intervention1: NIL: NIL
Sponsors
Sun Pharma Advanced Research Company Ltd, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri-E, Mumbai-400093, Maharashtra, India.
Eligibility
Inclusion criteria
Inclusion criteria: 18 years of age or older Either gender and any race,taking Latanoprost (containing BAK) monotherapy at least 12 months,tear break up time less than 6 seconds
Exclusion criteria
Exclusion criteria: Participation in another clinical study within the last thirty (30) days,Clinically significant systemic disease, which might interfere with the study,History of non-compliance to medical regimens or unwilling to comply with the study protocol,Refusal or inability to give written informed consent,Angle closure glaucoma or a history of acute angle closure treated with a peripheral iridotomy,Progressive retinal or optic nerve disease apart from glaucoma,Any opacity or subject uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber,Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tear break up timeTimepoint: at week 8 | — |
Secondary
| Measure | Time frame |
|---|---|
| Inferior corneal staining,Conjunctival hyperemia grading,Intra ocular pressure,Ocular surface disease.Timepoint: at week 8 | — |
Countries
India
Contacts
Public ContactDr Mudgal Kothekar MD
Sun Pharma Advanced Research Company Limited
Outcome results
None listed